2.50
Hdl Handle:
http://hdl.handle.net/10547/578743
Title:
Infrequent expression of the cancer-testis antigen, PASD1, in ovarian cancer
Authors:
Khan, Ghazala; Brooks, Suzanne E.; Mills, Ken I.; Guinn, Barbara-Ann
Abstract:
Ovarian cancer is very treatable in the early stages of disease; however, it is usually detected in the later stages, at which time, treatment is no longer as effective. If discovered early (Stage I), there is a 90% chance of five-year survival. Therefore, it is imperative that early-stage biomarkers are identified to enhance the early detection of ovarian cancer. Cancer-testis antigens (CTAs), such as Per ARNT SIM (PAS) domain containing 1 (PASD1), are unique in that their expression is restricted to immunologically restricted sites, such as the testis and placenta, which do not express MHC class I, and cancer, making them ideally positioned to act as targets for immunotherapy as well as potential biomarkers for cancer detection where expressed. We examined the expression of PASD1a and b in a number of cell lines, as well as eight healthy ovary samples, eight normal adjacent ovarian tissues, and 191 ovarian cancer tissues, which were predominantly stage I (n = 164) and stage II (n = 14) disease. We found that despite the positive staining of skin cancer, only one stage Ic ovarian cancer patient tissue expressed PASD1a and b at detectable levels. This may reflect the predominantly stage I ovarian cancer samples examined. To examine the restriction of PASD1 expression, we examined endometrial tissue arrays and found no expression in 30 malignant tumor tissues, 23 cases of hyperplasia, or 16 normal endometrial tissues. Our study suggests that the search for a single cancer-testes antigen/biomarker that can detect early ovarian cancer must continue.
Affiliation:
University of Bedfordshire; Southampton General Hospital; Queen’s University Belfast
Citation:
Khan, G., Brooks, S.E., Mills, K.I. & Guinn, B.A. (2015) 'Infrequent expression of the cancer-testis antigen, PASD1, in ovarian cancer' Biomarkers in Cancer, Vol 7, pp.31-38.
Publisher:
Libertas Academica
Journal:
Biomarkers in Cancer
Issue Date:
Aug-2015
URI:
http://hdl.handle.net/10547/578743
DOI:
10.4137/BIC.S28378
PubMed Central ID:
PMC4539101
Additional Links:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4539101/
Type:
Article
Language:
en
ISSN:
1179-299X
Sponsors:
This work was funded by Research Investment Program funding at the University of Bedfordshire. Thanks to Professor Alison Banham and Mrs Linden Lyne for providing the PASD1 antibody.
Appears in Collections:
Biomedicine and Nutrition Research Group

Full metadata record

DC FieldValue Language
dc.contributor.authorKhan, Ghazalaen
dc.contributor.authorBrooks, Suzanne E.en
dc.contributor.authorMills, Ken I.en
dc.contributor.authorGuinn, Barbara-Annen
dc.date.accessioned2015-09-25T10:03:20Zen
dc.date.available2015-09-25T10:03:20Zen
dc.date.issued2015-08en
dc.identifier.citationKhan, G., Brooks, S.E., Mills, K.I. & Guinn, B.A. (2015) 'Infrequent expression of the cancer-testis antigen, PASD1, in ovarian cancer' Biomarkers in Cancer, Vol 7, pp.31-38.en
dc.identifier.issn1179-299Xen
dc.identifier.doi10.4137/BIC.S28378en
dc.identifier.urihttp://hdl.handle.net/10547/578743en
dc.description.abstractOvarian cancer is very treatable in the early stages of disease; however, it is usually detected in the later stages, at which time, treatment is no longer as effective. If discovered early (Stage I), there is a 90% chance of five-year survival. Therefore, it is imperative that early-stage biomarkers are identified to enhance the early detection of ovarian cancer. Cancer-testis antigens (CTAs), such as Per ARNT SIM (PAS) domain containing 1 (PASD1), are unique in that their expression is restricted to immunologically restricted sites, such as the testis and placenta, which do not express MHC class I, and cancer, making them ideally positioned to act as targets for immunotherapy as well as potential biomarkers for cancer detection where expressed. We examined the expression of PASD1a and b in a number of cell lines, as well as eight healthy ovary samples, eight normal adjacent ovarian tissues, and 191 ovarian cancer tissues, which were predominantly stage I (n = 164) and stage II (n = 14) disease. We found that despite the positive staining of skin cancer, only one stage Ic ovarian cancer patient tissue expressed PASD1a and b at detectable levels. This may reflect the predominantly stage I ovarian cancer samples examined. To examine the restriction of PASD1 expression, we examined endometrial tissue arrays and found no expression in 30 malignant tumor tissues, 23 cases of hyperplasia, or 16 normal endometrial tissues. Our study suggests that the search for a single cancer-testes antigen/biomarker that can detect early ovarian cancer must continue.en
dc.description.sponsorshipThis work was funded by Research Investment Program funding at the University of Bedfordshire. Thanks to Professor Alison Banham and Mrs Linden Lyne for providing the PASD1 antibody.en
dc.language.isoenen
dc.publisherLibertas Academicaen
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC4539101/en
dc.subjectbiomarkeren
dc.subjectovarian canceren
dc.subjectPASD1en
dc.subjecthumanen
dc.subjectcancer-testis antigenen
dc.subjectcanceren
dc.titleInfrequent expression of the cancer-testis antigen, PASD1, in ovarian canceren
dc.typeArticleen
dc.contributor.departmentUniversity of Bedfordshireen
dc.contributor.departmentSouthampton General Hospitalen
dc.contributor.departmentQueen’s University Belfasten
dc.identifier.journalBiomarkers in Canceren
dc.identifier.pmcidPMC4539101en
All Items in UOBREP are protected by copyright, with all rights reserved, unless otherwise indicated.